These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 12747902

  • 1. Combined salmeterol and fluticasone for COPD.
    MacAllister R.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747902
    [No Abstract] [Full Text] [Related]

  • 2. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

  • 3. Combined salmeterol and fluticasone for COPD.
    Pakhale SS, Goldstein RS.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747904
    [No Abstract] [Full Text] [Related]

  • 4. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec 10; 17(98):229. PubMed ID: 19418648
    [Abstract] [Full Text] [Related]

  • 5. Combined salmeterol and fluticasone for COPD.
    Thirstrup S, Kampmann JP.
    Lancet; 2003 May 10; 361(9369):1650-1; author reply 1652-3. PubMed ID: 12747900
    [No Abstract] [Full Text] [Related]

  • 6. Combined salmeterol and fluticasone for COPD.
    Khamis RY, Rajakulasingam RK.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747905
    [No Abstract] [Full Text] [Related]

  • 7. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, Dai LM.
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov 10; 31(11):811-4. PubMed ID: 19080533
    [Abstract] [Full Text] [Related]

  • 8. Combined salmeterol and fluticasone for COPD.
    Hyde C, Dretzke J.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747903
    [No Abstract] [Full Text] [Related]

  • 9. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, Cosmic COPD and Serentide: A Multi-Center Intervention and Characterization Study Group.
    Rev Port Pneumol; 2005 May 10; 11(6):587-9. PubMed ID: 16514718
    [No Abstract] [Full Text] [Related]

  • 10. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec 10; 16(92):257-8. PubMed ID: 18092426
    [No Abstract] [Full Text] [Related]

  • 11. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 10; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 12. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 15; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 14. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov 13; 145(46):47. PubMed ID: 14699834
    [No Abstract] [Full Text] [Related]

  • 15. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED, van Dyk M, Sagriotis A.
    Pulm Pharmacol Ther; 2008 Nov 13; 21(1):20-5. PubMed ID: 17118684
    [Abstract] [Full Text] [Related]

  • 16. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, Ställberg B, Johansson G.
    J Intern Med; 2013 Jun 13; 273(6):584-94. PubMed ID: 23495860
    [Abstract] [Full Text] [Related]

  • 17. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J.
    Respirology; 2011 Jan 13; 16(1):95-101. PubMed ID: 20920142
    [Abstract] [Full Text] [Related]

  • 18. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis.
    Liu Y, Shi H, Sun X, Zhang D, Zhang Y, Yang K, Mi L, Li M.
    Eur J Intern Med; 2014 Jun 13; 25(5):491-5. PubMed ID: 24816076
    [Abstract] [Full Text] [Related]

  • 19. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
    Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK, SCO30005 Study Group.
    Am J Respir Crit Care Med; 2006 Apr 01; 173(7):736-43. PubMed ID: 16424444
    [Abstract] [Full Text] [Related]

  • 20. Survival in COPD patients after regular use of fluticasone propionate and salmeterol.
    Marchand E.
    Eur Respir J; 2003 Mar 01; 21(3):559-60; author reply 560. PubMed ID: 12662020
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.